A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma

Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to a phase II trial evaluating DFMO...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Lewis, Elizabeth C., Kraveka, Jacqueline M., Ferguson, William, Eslin, Don, Brown, Valerie I., Bergendahl, Genevieve, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Zage, Peter, Rawwas, Jawhar, Rich, Maria, Lorenzi, Elizabeth, Broglio, Kristine, Berry, Donald, Saulnier Sholler, Giselle L.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Cancer Therapy and Prevention
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586843/
https://ncbi.nlm.nih.gov/pubmed/32391579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33044
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars